On 24 June 2026, the Food and Drug Department, Ministry of Health, Lao PDR issued a certificate of drug registration for ALIVOSO® (vosoritide) under registration number 06-LM-10040-26.
As registered, vosoritide is a C-type natriuretic peptide (CNP) analog indicated to increase linear growth in pediatric patients with achondroplasia with open epiphyses.
ALIVOSO is a prescription medicine, manufactured by Alliance Pharmaceutical Co., Ltd at Simmanoneua Village, Hadsayfong District, Vientiane Capital, and supplied to authorized distributors in Lao PDR. It is presented as a white to yellow lyophilized powder for reconstitution, in a co-pack containing ten single-dose vials of vosoritide, ten vials of sterile water for injection, ten transfer needles and ten administration syringes.
The approved prescribing information, including dosage, contraindications, warnings and adverse effects, is published on the ALIVOSO product page.
Reporting a side effect or quality problem
Healthcare professionals, distributors and patients can report a suspected side effect, a quality problem or a suspected counterfeit product to our pharmacovigilance team using the medicine safety form.
Official updates from Laos Alliance Pharmaceutical Group — investments, milestones and press releases.
